4564.T Stock Surges 7.4% on Heavy Trading Volume, 21 Apr 2026

OncoTherapy Science, Inc. (4564.T) is trading at ¥29.0 on the JPX today, up 7.4% with exceptional volume. The Japanese biotech company saw 93.9 million shares change hands, well above its 75.7 million average. This intraday surge reflects strong investor interest in the cancer-focused developer. 4564.T stock has climbed 47.6% year-to-date, though the company remains unprofitable with a negative EPS of -2.83. The stock trades at a premium valuation with a price-to-sales ratio of 13.6x, signaling high growth expectations for its clinical pipeline.

4564.T Stock Price Action and Technical Setup

OncoTherapy Science opened at ¥29.0 today and hit its day high at the same level. The stock trades well above its 50-day moving average of ¥22.18, showing sustained upward momentum. The 52-week range spans ¥19.0 to ¥35.0, placing current prices near the upper band. Technical indicators show overbought conditions with RSI at 69.6 and stochastic %K at 83.97, suggesting potential pullback risk. However, the ADX reading of 38.61 confirms a strong trend is in place. Volume surge to 93.9 million shares (24% above average) validates the buying pressure behind today’s move.

Market Sentiment: Trading Activity and Liquidation Dynamics

The Money Flow Index at 68.14 indicates strong institutional accumulation despite overbought technicals. On-Balance Volume reached 903.3 million, reflecting consistent buying throughout the session. The Awesome Oscillator at 4.34 and positive MACD histogram of 0.57 suggest bullish momentum remains intact. Rate of Change at 47.62% shows explosive short-term strength. However, Williams %R at -23.08 hints at potential consolidation. Traders should monitor whether volume sustains above 75 million shares to confirm the breakout is genuine.

OncoTherapy Science Pipeline and Clinical Development

OncoTherapy Science develops multiple cancer therapies from its Kawasaki headquarters. OTS167, a maternal embryonic leucine zipper kinase inhibitor, is in Phase I/II trials for acute myeloid leukemia and Phase I for breast cancer. OTS964 targets various cancer types as a T-LAK cell-originated protein kinase inhibitor. The company’s cancer-specific peptide vaccine S-588410 reached Phase III trials for esophageal cancer and Phase II for bladder cancer. Additional programs include S-488210 and S-588210 in early phases. The company also develops antibody drugs like OTSA101 for synovial sarcoma and KHK6640 for Alzheimer’s disease, diversifying revenue potential beyond oncology.

Financial Metrics and Valuation Assessment

4564.T stock trades at a price-to-book ratio of 5.23x against book value of ¥5.93 per share. The enterprise value stands at ¥8.48 trillion with a market cap of ¥10.65 billion. Revenue per share reached ¥2.17, while net income per share was -¥2.44, reflecting R&D intensity. The company maintains a strong balance sheet with cash per share of ¥6.06 and a current ratio of 8.51x. However, negative profitability metrics persist: ROE at -63% and ROA at -35.5%. Research and development consumes 65.8% of revenue, typical for early-stage biotech. Track 4564.T on Meyka for real-time updates on financial developments.

Growth Trajectory and Year-to-Date Performance

OncoTherapy Science has delivered impressive returns in 2026, with 4564.T stock climbing 47.6% year-to-date. Revenue grew 22.9% year-over-year, while gross profit surged 92.8%. Operating income increased 28.8%, and net income rose 36.7% despite remaining negative. EPS growth accelerated 48.4%, outpacing revenue expansion. The company’s three-year revenue growth per share stands at -53.3%, indicating earlier challenges. However, recent momentum suggests a turnaround. Operating cash flow and free cash flow both grew approximately 33.6% and 33.7% respectively, showing improving operational efficiency.

Meyka AI Rating and Price Forecast Analysis

Meyka AI rates 4564.T with a grade of B and a HOLD suggestion, with a total score of 66.2 out of 100. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. The rating reflects balanced risk-reward despite current overbought technicals. Meyka AI’s forecast model projects ¥17.31 for the full year 2026, implying 40% downside from today’s price. The three-year forecast stands at ¥12.52, and the five-year projection at ¥7.76. These forecasts are model-based projections and not guarantees. The company’s C- rating from fundamental analysis recommends Strong Sell, conflicting with technical strength.

Final Thoughts

OncoTherapy Science (4564.T) demonstrates conflicting signals on 21 April 2026. The stock’s 7.4% intraday surge on heavy volume reflects strong technical momentum and investor enthusiasm for its cancer pipeline. However, fundamental metrics paint a cautious picture: negative profitability, high valuation multiples, and a C- rating warrant careful consideration. The company’s R&D-heavy model requires sustained clinical success to justify current pricing. While year-to-date gains of 47.6% are impressive, Meyka AI’s price forecasts suggest significant downside risk over longer timeframes. Investors should monitor upcoming earnings on 11 May 2026 and clinical trial updates. The stock remains speculative, suitable only for risk-tolerant portfolios with conviction in the biotech pipeline’s potential.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.